Could Focal Treatment for Intermediate-Risk Prostate Cancer Improve Outcomes? - European Medical Journal

Could Focal Treatment for Intermediate-Risk Prostate Cancer Improve Outcomes?

1 Mins
Urology

NEW findings show that MRI-guided high-intensity focused ultrasound (HIFU) to deliver focal therapy could improve quality of life for patients with intermediate-risk prostate cancer.

A multicentre, single-arm, Phase IIb study to evaluate whether use of MRI-guided HIFU could delay or eliminate the need for whole-gland treatments for intermediate-risk prostate cancer has shown that this could be an effective treatment option.

The study enrolled 101 male patients aged 50 and over with a diagnosis of primary, unilateral, MRI-visible, Grade group 2 or 3, intermediate-risk adenocarcinoma of the prostate, who had not received treatment previously. To assess response, biopsies of the treated area were taken at 6- and 24-months post-treatment, and patient reported outcomes were evaluated.

Behfar Ehdaie, Memorial Sloan Kettering Cancer Center, New York City, USA, and colleagues report that of the 101 patients included, “96% had no evidence of Grade group 2 or higher prostate cancer on 6-month MRI-targeted and systematic biopsy of the treated area of the prostate gland.” They also state that 89 patients were followed up at 24 months, and 88% of these showed no evidence of Grade group 2 or higher prostate cancer in the treated area. 76% had no evidence of Grade group 2 or higher disease anywhere in the prostate at 6 months, reducing to 60% at 24 months. At the time of the 6-month biopsy, 19 of the 101 men included had a newly detected Grade group 2 or higher cancer outside of the treated area.

The team also disclosed that quality of life outcomes and functional outcomes compared “very favourably” to patient-reported outcomes from studies of whole-gland treatments such as radical prostatectomy or radiotherapy, which are “associated with substantial and persistent side-effects that impact quality of life.”

Overall satisfaction and erectile function scores were lower 24 months following MRI-guided HIFU than at baseline. In response to this, the authors commented: “Although the difference in mean erectile function scores was significant, the small difference should be interpreted across the range of the overall score and considered across the time range of 2 years, in which small decreases in erectile function score are expected without treatment, making this change statistically but not clinically significant.”

Limitations of the study include the length of follow-up, and that it was a single-arm study. The researchers stated that 24-month biopsy isn’t an adequate endpoint as metastases in intermediate-risk prostate cancer are unlikely during a 2-year period. Future studies could be followed up over a longer time period, and include control arms in order to assess whether there is clinical benefit to treating those with intermediate-risk prostate cancer with MRI-guided HIFU versus active surveillance.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>